List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3727969/publications.pdf Version: 2024-02-01

202 papers	14,353 citations	71102 41 h-index	21540 114 g-index
211	211	211	14351
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Annals of the Rheumatic Diseases, 2017, 76, 960-977.	0.9	3,366
2	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Annals of the Rheumatic Diseases, 2020, 79, 685-699.	0.9	1,860
3	EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis. Annals of the Rheumatic Diseases, 2013, 72, 1125-1135.	0.9	1,033
4	The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Annals of the Rheumatic Diseases, 2016, 75, 795-810.	0.9	780
5	EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Annals of the Rheumatic Diseases, 2008, 67, 536-541.	0.9	639
6	Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Annals of the Rheumatic Diseases, 2006, 65, 285-293.	0.9	402
7	Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Annals of the Rheumatic Diseases, 2002, 61, 718-722.	0.9	395
8	EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Annals of the Rheumatic Diseases, 2007, 66, 1560-1567.	0.9	325
9	Sex Hormones and Glucocorticoids: Interactions with the Immune System. Annals of the New York Academy of Sciences, 1999, 876, 102-118.	3.8	234
10	EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Annals of the Rheumatic Diseases, 2013, 72, 1905-1913.	0.9	220
11	European League Against Rheumatism recommendations for the inclusion of patient representatives in scientific projects. Annals of the Rheumatic Diseases, 2011, 70, 722-726.	0.9	208
12	EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees. Annals of the Rheumatic Diseases, 2004, 63, 1172-1176.	0.9	183
13	Effect of Vitamin D Supplementation, Omega-3 Fatty Acid Supplementation, or a Strength-Training Exercise Program on Clinical Outcomes in Older Adults. JAMA - Journal of the American Medical Association, 2020, 324, 1855.	7.4	180
14	Topical NSAIDs for chronic musculoskeletal pain in adults. The Cochrane Library, 2020, 2020, CD007400.	2.8	168
15	The role of pregnancy in the course and aetiology of rheumatoid arthritis. Clinical Rheumatology, 1992, 11, 189-194.	2.2	165
16	Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice. Annals of the Rheumatic Diseases, 2010, 69, 1913-1919.	0.9	159
17	The prevalence of severe fatigue in rheumatic diseases: an international study. Clinical Rheumatology, 2016, 35, 409-415.	2.2	147
18	The accuracy of osteoporotic fracture risk prediction tools: a systematic review and meta-analysis. Annals of the Rheumatic Diseases, 2015, 74, 1958-1967.	0.9	128

#	Article	IF	CITATIONS
19	Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course. Journal of Clinical Medicine, 2019, 8, 2013.	2.4	118
20	Patient and rheumatologist perspectives on glucocorticoids: an exercise to improve the implementation of the European League Against Rheumatism (EULAR) recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Annals of the Rheumatic Diseases, 2010, 69, 1015-1021.	0.9	117
21	EULAR/EFORT recommendations for management of patients older than 50â€years with a fragility fracture and prevention of subsequent fractures. Annals of the Rheumatic Diseases, 2017, 76, 802-810.	0.9	111
22	The molecular basis for the effectiveness, toxicity, and resistance to glucocorticoids: focus on the treatment of rheumatoid arthritis. Scandinavian Journal of Rheumatology, 2005, 34, 14-21.	1.1	107
23	Topical diclofenac and its role in pain and inflammation: an evidence-based review. Current Medical Research and Opinion, 2008, 24, 925-950.	1.9	93
24	Preventing progression from arthralgia to arthritis: targeting the right patients. Nature Reviews Rheumatology, 2018, 14, 32-41.	8.0	91
25	Derivation and validation of the SLE Disease Activity Score (SLE-DAS): a new SLE continuous measure with high sensitivity for changes in disease activity. Annals of the Rheumatic Diseases, 2019, 78, 365-371.	0.9	88
26	Suppressing Inflammation in Rheumatoid Arthritis: Does Patient Global Assessment Blur the Target? A Practiceâ€Based Call for a Paradigm Change. Arthritis Care and Research, 2018, 70, 369-378.	3.4	84
27	Frequency and functional activity of Th17, Tc17 and other T-cell subsets in Systemic Lupus Erythematosus. Cellular Immunology, 2010, 264, 97-103.	3.0	82
28	A RANDOMIZED TRIAL OF TESTOSTERONE THERAPY IN MALES WITH RHEUMATOID ARTHRITIS. Rheumatology, 1996, 35, 568-573.	1.9	81
29	Comparative effectiveness and predictors of response to tumour necrosis factor inhibitor therapies in rheumatoid arthritis. Rheumatology, 2012, 51, 2020-2026.	1.9	78
30	Potential roles for CD8+ T cells in rheumatoid arthritis. Autoimmunity Reviews, 2013, 12, 401-409.	5.8	78
31	The effects of gender and sex hormones on outcome in rheumatoid arthritis. Bailliere's Clinical Rheumatology, 1992, 6, 193-219.	1.0	77
32	Drivers of patient global assessment in patients with rheumatoid arthritis who are close to remission: an analysis of 1588 patients. Rheumatology, 2017, 56, 1573-1578.	1.9	71
33	NK cells dysfunction in systemic lupus erythematosus: relation to disease activity. Clinical Rheumatology, 2013, 32, 805-813.	2.2	69
34	CD8+ T Cell Profiles in Patients With Rheumatoid Arthritis and Their Relationship to Disease Activity. Arthritis and Rheumatology, 2015, 67, 363-371.	5.6	67
35	Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial. Annals of the Rheumatic Diseases, 2022, 81, 925-936.	0.9	59
36	Sex steroids affect glucocorticoid response to chronic inflammation and to interleukin-1. Journal of Endocrinology, 1993, 136, 389-397.	2.6	56

#	Article	IF	CITATIONS
37	Effects of Testosterone, 17beta-Estradiol, and Downstream Estrogens on Cytokine Secretion from Human Leukocytes in the Presence and Absence of Cortisol. Annals of the New York Academy of Sciences, 2006, 1069, 168-182.	3.8	56
38	The burden of osteoporotic hip fractures in Portugal: costs, health related quality of life and mortality. Osteoporosis International, 2015, 26, 2623-2630.	3.1	54
39	Perturbations of hypothalamic-pituitary-gonadal (HPG) axis and adrenal androgen (AA) functions in rheumatoid arthritis. Bailliere's Clinical Rheumatology, 1996, 10, 295-332.	1.0	50
40	Functional characterization of peripheral blood dendritic cells and monocytes in systemic lupus erythematosus. Rheumatology International, 2012, 32, 863-869.	3.0	46
41	Identification of clinical predictors of flare in systemic lupus erythematosus patients: a 24-month prospective cohort study. Rheumatology, 2014, 53, 85-89.	1.9	45
42	Impact of impaired morning function on the lives and well-being of patients with rheumatoid arthritis. Scandinavian Journal of Rheumatology, 2011, 40, 6-11.	1.1	44
43	Erectile dysfunction is frequent in systemic sclerosis and associated with severe disease: a study of the EULAR Scleroderma Trial and Research group. Arthritis Research and Therapy, 2012, 14, R37.	3.5	41
44	Impact of Patient's Global Assessment on Achieving Remission in Patients With Rheumatoid Arthritis: A Multinational Study Using the METEOR Database. Arthritis Care and Research, 2019, 71, 1317-1325.	3.4	41
45	Ultrasonography for the Assessment of Skin in Systemic Sclerosis: A Systematic Review. Arthritis Care and Research, 2019, 71, 563-574.	3.4	39
46	JOINT SPACE IN RADIOLOGICALLY NORMAL KNEES. Rheumatology, 1991, 30, 426-428.	1.9	38
47	Dual target strategy: a proposal to mitigate the risk of overtreatment and enhance patient satisfaction in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2019, 78, e109-e109.	0.9	35
48	Developments in Glucocorticoid Therapy. Rheumatic Disease Clinics of North America, 2005, 31, 1-17.	1.9	34
49	Operational Definition of Active and Healthy Aging (AHA): The European Innovation Partnership (EIP) on AHA Reference Site Questionnaire: Montpellier October 20–21, 2014, Lisbon July 2, 2015. Journal of the American Medical Directors Association, 2015, 16, 1020-1026.	2.5	33
50	Update of the fracture risk prediction tool FRAX: a systematic review of potential cohorts and analysis plan. Osteoporosis International, 2022, 33, 2103-2136.	3.1	33
51	Harm, benefit and costs associated with low-dose glucocorticoids added to the treatment strategies for rheumatoid arthritis in elderly patients (GLORIA trial): study protocol for a randomised controlled trial. Trials, 2018, 19, 67.	1.6	32
52	Revisiting the use of remission criteria for rheumatoid arthritis by excluding patient global assessment: an individual meta-analysis of 5792 patients. Annals of the Rheumatic Diseases, 2021, 80, 293-303.	0.9	32
53	Destruction of articular cartilage by alpha2 macroglobulin elastase complexes: role in rheumatoid arthritis. Annals of the Rheumatic Diseases, 1999, 58, 109-113.	0.9	31
54	Invalidation in Patients with Rheumatic Diseases: Clinical and Psychological Framework. Journal of Rheumatology, 2017, 44, 512-518.	2.0	31

#	Article	IF	CITATIONS
55	Immunomodulatory effect of human bone marrowâ€derived mesenchymal stromal/stem cells on peripheral blood T cells from rheumatoid arthritis patients. Journal of Tissue Engineering and Regenerative Medicine, 2020, 14, 16-28.	2.7	30
56	Timing of onset affects arthritis presentation pattern in antisyntethase syndrome. Clinical and Experimental Rheumatology, 2018, 36, 44-49.	0.8	30
57	The impact of fatigue in rheumatoid arthritis and the challenges of its assessment. Rheumatology, 2019, 58, v3-v9.	1.9	29
58	Fibromyalgia position paper. Clinical and Experimental Rheumatology, 2021, 39, 186-193.	0.8	29
59	Polymyalgia Rheumatica (PMR) Special Interest Group at OMERACT 11: Outcomes of Importance for Patients with PMR. Journal of Rheumatology, 2014, 41, 819-823.	2.0	28
60	Increased frequencies of circulating CXCL10-, CXCL8- and CCL4-producing monocytes and Siglec-3-expressing myeloid dendritic cells in systemic sclerosis patients. Inflammation Research, 2018, 67, 169-177.	4.0	28
61	Effectiveness of non-pharmacological and non-surgical interventions for rheumatoid arthritis: an umbrella review. JBI Database of Systematic Reviews and Implementation Reports, 2019, 17, 1494-1531.	1.7	28
62	DO-HEALTH: Vitamin D3 - Omega-3 - Home exercise - Healthy aging and longevity trial - Design of a multinational clinical trial on healthy aging among European seniors. Contemporary Clinical Trials, 2021, 100, 106124.	1.8	28
63	Multitarget therapy of mycophenolate mofetil and cyclosporine A for induction treatment of refractory lupus nephritis. Lupus, 2018, 27, 1358-1362.	1.6	27
64	Pregnancy and Rheumatoid Arthritis: An Overview. American Journal of Reproductive Immunology, 1992, 28, 222-225.	1.2	26
65	Safety of Iow―to mediumâ€dose glucocorticoid treatment in rheumatoid arthritis: myths and reality over the years. Annals of the New York Academy of Sciences, 2014, 1318, 41-49.	3.8	26
66	Characterization of damage in Portuguese lupus patients: analysis of a national lupus registry. Lupus, 2015, 24, 256-262.	1.6	26
67	Common Evaluations of Disease Activity in Rheumatoid Arthritis Reach Discordant Classifications across Different Populations. Frontiers in Medicine, 2018, 5, 40.	2.6	26
68	EpiReumaPt- the study of rheumatic and musculoskeletal diseases in Portugal: a detailed view of the methodology. Acta Reumatológica Portuguesa, 2015, 40, 110-24.	0.2	26
69	Protective effect of androgens against inflammation induced cartilage degradation in male rodents Annals of the Rheumatic Diseases, 1993, 52, 285-291.	0.9	25
70	Cost-Effectiveness of Intervention Thresholds for the Treatment of Osteoporosis Based on FRAX® in Portugal. Calcified Tissue International, 2016, 99, 131-141.	3.1	25
71	SARS-CoV-2 outbreak in immune-mediated inflammatory diseases: the Euro-COVIMID multicentre cross-sectional study. Lancet Rheumatology, The, 2021, 3, e481-e488.	3.9	25
72	Quality indicators in rheumatoid arthritis: results from the METEOR database. Rheumatology, 2015, 54, 1630-1639.	1.9	23

#	Article	IF	CITATIONS
73	DAS28, CDAI and SDAI cut-offs do not translate the same information: results from the Rheumatic Diseases Portuguese Register Reuma.pt. Rheumatology, 2015, 54, 286-291.	1.9	22
74	Prevalence of vitamin D deficiency and its predictors in the Portuguese population: a nationwide population-based study. Archives of Osteoporosis, 2020, 15, 36.	2.4	22
75	A case of infliximab-induced lupus in a patient with ankylosing spondylitis: is it safe switch to another anti-TNF-α agent?. Clinical Rheumatology, 2013, 32, 1819-1822.	2.2	20
76	Revisiting the Toxicity of Low-Dose Glucocorticoids: Risks and Fears. Annals of the New York Academy of Sciences, 2006, 1069, 275-288.	3.8	19
77	Measurement invariance of the Illness Invalidation Inventory (3*I) across language, rheumatic disease and gender. Annals of the Rheumatic Diseases, 2014, 73, 551-556.	0.9	19
78	Comparative Effectiveness of Tocilizumab and TNF Inhibitors in Rheumatoid Arthritis Patients: Data from the Rheumatic Diseases Portuguese Register, Reuma.pt. BioMed Research International, 2015, 2015, 1-13.	1.9	19
79	Rheumatology training experience across Europe: analysis of core competences. Arthritis Research and Therapy, 2016, 18, 213.	3.5	19
80	Determinants of happiness and quality of life in patients with rheumatoid arthritis: a structural equation modelling approach. Annals of the Rheumatic Diseases, 2018, 77, annrheumdis-2017-212934.	0.9	19
81	â€~It can't be zero!' Difficulties in completing patient global assessment in rheumatoid arthritis: a mixed methods study. Rheumatology, 2020, 59, 1137-1147.	1.9	19
82	Differential Male and Female Adrenal Cortical Steroid Hormone and Cortisol Responses to Interleukinâ€6 in Humans. Annals of the New York Academy of Sciences, 2002, 966, 68-72.	3.8	18
83	Differences and similarities in rheumatology specialty training programmes across European countries. Annals of the Rheumatic Diseases, 2015, 74, 1183-1187.	0.9	18
84	Safety of Glucocorticoids in Rheumatoid Arthritis: Evidence from Recent Clinical Trials. NeuroImmunoModulation, 2015, 22, 57-65.	1.8	18
85	Do we need bone mineral density to estimate osteoporotic fracture risk? A 10-year prospective multicentre validation study. RMD Open, 2017, 3, e000509.	3.8	18
86	Early predictors of renal outcome in patients with proliferative lupus nephritis: a 36-month cohort study. Rheumatology, 2021, 60, 5134-5141.	1.9	18
87	The patient global assessment in RA precludes the majority of patients otherwise in remission to reach this status in clinical practice. Should we continue to ignore this?. Seminars in Arthritis and Rheumatism, 2020, 50, 583-585.	3.4	18
88	Distribution and functional plasticity of peripheral blood Th(c)17 and Th(c)1 in rheumatoid arthritis. Rheumatology International, 2013, 33, 2093-2099.	3.0	17
89	Barriers and potential solutions in the recruitment and retention of older patients in clinical trials—lessons learned from six large multicentre randomized controlled trials. Age and Ageing, 2021, 50, 1988-1996.	1.6	17
90	High patient global assessment scores in patients with rheumatoid arthritis otherwise in remission do not reflect subclinical inflammation. Joint Bone Spine, 2021, 88, 105242.	1.6	17

#	Article	IF	CITATIONS
91	Soft tissue injections. Best Practice and Research in Clinical Rheumatology, 2005, 19, 503-527.	3.3	16
92	Coexisting primary Sjögren's syndrome and sarcoidosis: coincidence, mutually exclusive conditions or syndrome?. Rheumatology International, 2014, 34, 1619-1622.	3.0	16
93	CD38, CD81 and BAFFR combined expression by transitional B cells distinguishes active from inactive systemic lupus erythematosus. Clinical and Experimental Medicine, 2016, 16, 227-232.	3.6	16
94	Effects of vitamin D, omega-3 fatty acids, and a simple home strength exercise program on fall prevention: the DO-HEALTH randomized clinical trial. American Journal of Clinical Nutrition, 2022, 115, 1311-1321.	4.7	16
95	Rheumatology education in Europe: results of a survey of young rheumatologists. Clinical and Experimental Rheumatology, 2011, 29, 843-5.	0.8	16
96	Cervical complications of rheumatoid arthritis. Annals of the Rheumatic Diseases, 2004, 64, 355-358.	0.9	15
97	Selecting men for bone densitometry: performance of osteoporosis risk assessment tools in Portuguese men. Osteoporosis International, 2010, 21, 977-983.	3.1	15
98	<i>TRAF1/C5</i> but Not <i>PTPRC</i> Variants Are Potential Predictors of Rheumatoid Arthritis Response to Anti-Tumor Necrosis Factor Therapy. BioMed Research International, 2015, 2015, 1-9.	1.9	15
99	Subset-specific alterations in frequencies and functional signatures of Î <sup>3</sup> δT cells in systemic sclerosis patients. Inflammation Research, 2016, 65, 985-994.	4.0	15
100	Validating Rheumatoid Arthritis Remission Using the Patients' Perspective: Results from a Special Interest Group at OMERACT 2016. Journal of Rheumatology, 2017, 44, 1889-1893.	2.0	15
101	Brief Report: Smoking in Systemic Sclerosis: A Longitudinal European Scleroderma Trials and Research Group Study. Arthritis and Rheumatology, 2018, 70, 1829-1834.	5.6	15
102	Prevalence and incidence of iron deficiency in European community-dwelling older adults: an observational analysis of the DO-HEALTH trial. Aging Clinical and Experimental Research, 2022, 34, 2205-2215.	2.9	15
103	Applying science in practice: the optimization of biological therapy in rheumatoid arthritis. Arthritis Research and Therapy, 2010, 12, 220.	3.5	14
104	Outcome Measures in Polymyalgia Rheumatica. A Systematic Review. Journal of Rheumatology, 2015, 42, 2503-2511.	2.0	14
105	Influence of the different "patient global assessment―formulations on disease activity score by different indices in rheumatoid arthritis. Clinical Rheumatology, 2018, 37, 1963-1969.	2.2	14
106	Ultrasound and elastography in the assessment of skin involvement in systemic sclerosis: A systematic literature review focusing on validation and standardization – WSF Skin Ultrasound Group. Seminars in Arthritis and Rheumatism, 2022, 52, 151954.	3.4	14
107	A preliminary study using virtual touch imaging and quantification for the assessment of skin stiffness in systemic sclerosis. Clinical and Experimental Rheumatology, 2016, 34 Suppl 100, 137-141.	0.8	14
108	Definition of low disease activity state based on the SLE-DAS: derivation and validation in a multicentre real-life cohort. Rheumatology, 2022, 61, 3309-3316.	1.9	14

#	Article	IF	CITATIONS
109	A comparison between nailfold capillaroscopy patterns in adulthood in juvenile and adult-onset systemic sclerosis: A EUSTAR exploratory study. Microvascular Research, 2015, 102, 19-24.	2.5	13
110	How much of skin improvement over time in systemic sclerosis is due to normal ageing? A prospective study with shear-wave elastography. Arthritis Research and Therapy, 2020, 22, 50.	3.5	13
111	Patients' and rheumatologists' perspectives on the efficacy and safety of low-dose glucocorticoids in rheumatoid arthritis—an international survey within the GLORIA study. Rheumatology, 2021, 60, 3334-3342.	1.9	13
112	Combined Vitamin D, Omega-3 Fatty Acids, and a Simple Home Exercise Program May Reduce Cancer Risk Among Active Adults Aged 70 and Older: A Randomized Clinical Trial. Frontiers in Aging, 2022, 3, .	2.6	13
113	Exercise echocardiography for the assessment of pulmonary hypertension in systemic sclerosis: a systematic review. Arthritis Research and Therapy, 2016, 18, 153.	3.5	12
114	2019 EULAR points to consider for the assessment of competences in rheumatology specialty training. Annals of the Rheumatic Diseases, 2021, 80, 65-70.	0.9	12
115	Treating-to-target in rheumatology: Theory and practice. Best Practice and Research in Clinical Rheumatology, 2022, 36, 101735.	3.3	12
116	UEMS charter on the training of rheumatologists in Europe. Annals of the Rheumatic Diseases, 2008, 67, 555-558.	0.9	11
117	Progress towards improved non-pharmacological management of fibromyalgia. Joint Bone Spine, 2020, 87, 377-379.	1.6	11
118	Heat shock proteins: the missing link between hormonal and reproductive factors and rheumatoid arthritis?. Annals of the Rheumatic Diseases, 1991, 50, 735-739.	0.9	10
119	Exerciseâ€Induced Pulmonary Hypertension in Scleroderma Patients: A Common Finding but with Elusive Pathophysiology. Echocardiography, 2013, 30, 378-384.	0.9	10
120	Recent Patents on Impact of Lipopeptide on the Biofilm Formation onto Titanium and Stainless Steel Surfaces. Recent Patents on Biotechnology, 2020, 14, 49-62.	0.8	10
121	Validity and reliability of the EULAR instrument RAID.7 as a tool to assess individual domains of impact of disease in rheumatoid arthritis: a cross-sectional study of 671 patients. RMD Open, 2021, 7, e001539.	3.8	10
122	Patients- and physicians- priorities for improvement. The case of rheumatic diseases. Acta Reumatológica Portuguesa, 2010, 35, 192-9.	0.2	10
123	Th17 cells in systemic lupus erythematosus share functional features with Th17 cells from normal bone marrow and peripheral tissues. Clinical Rheumatology, 2012, 31, 483-491.	2.2	9
124	Chronic widespread pain and increased mortality: biopsychosocial interconnections. Annals of the Rheumatic Diseases, 2017, 77, annrheumdis-2017-211893.	0.9	9
125	Patient global assessment and radiographic progression in early arthritis: 3â€year results from the ESPOIR cohort. Arthritis Care and Research, 2020, 73, 1300-1305.	3.4	9
126	Relationships between Glucocorticoids and Gonadal Steroids in Rheumatoid Arthritis. Annals of the New York Academy of Sciences, 2002, 966, 158-165.	3.8	8

#	Article	IF	CITATIONS
127	Competencies in rheumatology: a European framework. Best Practice and Research in Clinical Rheumatology, 2009, 23, 145-160.	3.3	8
128	Milwaukee shoulder (and knee) syndrome. BMJ Case Reports, 2014, 2014, bcr2013202183-bcr2013202183.	0.5	8
129	Nailfold capillary abnormalities in erectile dysfunction of systemic sclerosis: a EUSTAR group analysis. Rheumatology, 2014, 53, 639-643.	1.9	8
130	Sera from patients with active systemic lupus erythematosus patients enhance the toll-like receptor 4 response in monocyte subsets. Journal of Inflammation, 2015, 12, 38.	3.4	8
131	The Portuguese Rheumatoid Arthritis Impact of Disease (RAID) score and its measurement equivalence in three countries: validation study using Rasch Models. Quality of Life Research, 2018, 27, 2909-2921.	3.1	8
132	Shared decisionâ€making in people with chronic disease: Integrating the biological, social and lived experiences is a key responsibility of nurses. Musculoskeletal Care, 2020, 18, 84-91.	1.4	8
133	Happiness, quality of life and their determinants among people with systemic sclerosis: a structural equation modelling approach. Rheumatology, 2021, 60, 4717-4727.	1.9	8
134	Definition of Treatment Targets in Rheumatoid Arthritis: Is It Time for Reappraisal?. Journal of Rheumatology, 2021, 48, 1763-1766.	2.0	8
135	Considerations and priorities for incorporating the patient perspective on remission in rheumatoid arthritis: An OMERACT 2020 special interest group report. Seminars in Arthritis and Rheumatism, 2021, 51, 1108-1112.	3.4	8
136	Gender Differences in Adrenal and Gonadal Responses to Inflammatory Aggression. Annals of the New York Academy of Sciences, 1999, 876, 148-151.	3.8	7
137	Assessment of Global Disease Activity in Rheumatoid Arthritis by Patients and Physicians. Journal of Clinical Rheumatology, 2015, 21, 349-354.	0.9	7
138	The importance of heat against antinutritional factors from Chenopodium quinoa seeds. Food Science and Technology, 2015, 35, 74-82.	1.7	7
139	Is current smoking status and its relationship to anti-cyclic citrullinated peptide antibodies a predictor of worse response to biological therapies in rheumatoid arthritis patients?. Scandinavian Journal of Rheumatology, 2018, 47, 360-363.	1.1	7
140	Depression, disability and sleep disturbance are the main explanatory factors of fatigue in rheumatoid arthritis: a path analysis model. Clinical and Experimental Rheumatology, 2020, 38, 314-321.	0.8	7
141	Prediction of Vertebral Fractures Is Specific for Gender and Site of Bone Mineral Density Measurement. Journal of Rheumatology, 2010, 37, 149-154.	2.0	6
142	Glucocorticoids Are Always Under Suspicion — Is the Perception of Their Risks Unbiased?. Journal of Rheumatology, 2018, 45, 293-296.	2.0	6
143	The Patient Experienced Symptom State (PESS): a patient-reported global outcome measure that may better reflect disease remission status. Rheumatology, 2020, 59, 3458-3467.	1.9	6
144	Developing a professional approach to work-based assessments in rheumatology. Best Practice and Research in Clinical Rheumatology, 2013, 27, 123-136.	3.3	5

#	Article	IF	CITATIONS
145	The controversy of using PGA to define remission in RA. Nature Reviews Rheumatology, 2018, 14, 245-245.	8.0	5
146	The many faces of IgC4-related disease: report of a case with inaugural recurrent aortic aneurism ruptures and literature review. Rheumatology International, 2018, 38, 1565-1570.	3.0	5
147	Attainment of the Patient-acceptable Symptom State in 548 patients with rheumatoid arthritis: Influence of demographic factors. Joint Bone Spine, 2021, 88, 105071.	1.6	5
148	Antimalarial treatment and minimizing prednisolone are associated with lower risk of infection in SLE: a 24-month prospective cohort study. Clinical Rheumatology, 2022, 41, 1069-1078.	2.2	5
149	A FRAX model for the estimation of osteoporotic fracture probability in Portugal. Acta Reumatológica Portuguesa, 2013, 38, 104-12.	0.2	5
150	The impact of patient global assessment in the definition of remission as a predictor of long-term radiographic damage in patients with rheumatoid arthritis: protocol for an individual patient data meta-analysis. Acta Reumatológica Portuguesa, 2018, 43, 52-60.	0.2	5
151	Human Bone Marrow Mesenchymal Stromal/Stem Cells Regulate the Proinflammatory Response of Monocytes and Myeloid Dendritic Cells from Patients with Rheumatoid Arthritis. Pharmaceutics, 2022, 14, 404.	4.5	5
152	Effectiveness of non-pharmacological and non-surgical interventions on the impact of rheumatoid arthritis. JBI Database of Systematic Reviews and Implementation Reports, 2019, 17, 22-27.	1.7	4
153	Performance of decision algorithms for the identification of low bone mineral density in Portuguese postmenopausal women. Acta Reumatológica Portuguesa, 2008, 33, 314-28.	0.2	4
154	Predictors of response to TNF blockers in patients with polyarticular psoriatic arthritis. Acta Reumatológica Portuguesa, 2017, 42, 55-65.	0.2	4
155	The Portuguese Society of Rheumatology position paper on the use of biosimilars - 2017 update. Acta ReumatolA³gica Portuguesa, 2017, 42, 219-228.	0.2	4
156	Diagnostic and therapeutic care pathway for fibromyalgia. Clinical and Experimental Rheumatology, 2021, 39, 120-127.	0.8	4
157	The safety of glucocorticoids in the treatment of inflammatory rheumatic disease: new evidence. Current Opinion in Rheumatology, 2022, 34, 179-186.	4.3	4
158	Unilateral calf hypertrophy and radiculopathy: an unusual association. BMJ Case Reports, 2016, 2016, bcr2016217744.	0.5	3
159	Association of 17 Definitions of Remission with Functional Status in a Large Clinical Practice Cohort of Patients with Rheumatoid Arthritis. Journal of Rheumatology, 2020, 47, 20-27.	2.0	3
160	Correspondence on â€~Re-examining remission definitions in rheumatoid arthritis: considering the 28-joint Disease Activity Score, C reactive protein level and patient global assessment'. Annals of the Rheumatic Diseases, 2023, 82, e183-e183.	0.9	3
161	Predictors of hospitalization in patients with systemic lupus erythematosus: a 10-year cohort study. Clinical Rheumatology, 0, , .	2.2	3
162	A questionnaire for listening to students' voices in the assessment of teaching quality in a classical medical school. Assessment and Evaluation in Higher Education, 2008, 33, 445-453.	5.6	2

#	Article	IF	CITATIONS
163	Clarifications needed, please. BMJ: British Medical Journal, 2011, 342, d2602-d2602.	2.3	2
164	OP0144-HPRâ€â€œit can't be zero― a qualitative study of patients' perspective on patient global assessment in rheumatoid arthritis. , 2017, , .		2
165	EULAR portfolio for Rheumatology training: a EULAR School of Rheumatology initiative. RMD Open, 2021, 7, e001684.	3.8	2
166	The impact of transducer frequency in ultrasound evaluation of subclinical skin involvement in limited cutaneous systemic sclerosis patients. Clinical and Experimental Rheumatology, 2019, 37 Suppl 119, 147-148.	0.8	2
167	Editorial: Osteoporosis in Rheumatic Diseases, What's New?. Frontiers in Medicine, 2021, 8, 808345.	2.6	2
168	Reply. Arthritis Care and Research, 2019, 71, 695-696.	3.4	1
169	Remarkable international variability in reasons for ineligibility and non-participation in the GLORIA trial. Scandinavian Journal of Rheumatology, 2019, 48, 340-341.	1.1	1
170	POS0055â€SARS-COV-2 OUTBREAK IN AUTOIMMUNE DISEASES: THE EURO-COVIMID STUDY. Annals of the Rheumatic Diseases, 2021, 80, 233-234.	0.9	1
171	THU0586â€ESTABLISHING THE KEY COMPONENTS OF A EULAR PORTFOLIO FOR TRAINING IN RHEUMATOLOGY EULAR SCHOOL OF RHEUMATOLOGY INITIATIVE. Annals of the Rheumatic Diseases, 2020, 79, 535.1-535.	∕: A 0.9	1
172	Correspondence on "Reâ€examining remission definitions in rheumatoid arthritis: considering the <scp>28â€Joint</scp> Disease Activity Score, Câ€reactive protein level and patient global assessment―by Felson et al. ACR Open Rheumatology, 2022, 4, 271-272.	2.1	1
173	Multidisciplinary Portuguese recommendations on DXA request and indication to treat in the prevention of fragility fractures. Acta ReumatolÃ <sup>3</sup> gica Portuguesa, 2016, 41, 305-321.	0.2	1
174	Can health care providers recognise a fibromyalgia personality?. Clinical and Experimental Rheumatology, 2017, 35 Suppl 105, 43-49.	0.8	1
175	General Practitioners and Rheumatologists: new bridges for a successful cooperation. Acta ReumatolÃ <sup>3</sup> gica Portuguesa, 2017, 42, 6-7.	0.2	1
176	Educational needs in people with ankylosing spondylitis and psoriatic arthritis: a cross-sectional study. Clinical and Experimental Rheumatology, 2020, 38, 282-288.	0.8	1
177	Fibromyalgia position paper. Clinical and Experimental Rheumatology, 2021, 39 Suppl 130, 186-193.	0.8	1
178	Dual-target strategy: fostering person-centered care in rheumatology. Acta Reumatológica Portuguesa, 2021, 46, 99-102.	0.2	1
179	Patient Experienced Symptom State in rheumatoid arthritis: sensitivity to change in disease activity and impact. Rheumatology, 2022, 62, 98-107.	1.9	1
180	Chapter 20 Hormonal Modulation of Autoimmune Diseases: Glucocorticoids. Handbook of Systemic Autoimmune Diseases, 2008, 9, 229-240.	0.1	0

#	Article	IF	CITATIONS
181	Preface. Best Practice and Research in Clinical Rheumatology, 2009, 23, 125.	3.3	Ο
182	Assessment of cardiovascular risk in rheumatoid arthritis patients. European Journal of Internal Medicine, 2013, 24, e135-e136.	2.2	0
183	Preface. Best Practice and Research in Clinical Rheumatology, 2013, 27, 121.	3.3	0
184	A10.5â€Comparative Effectiveness of Biological Therapies in Rheumatoid Arthritis is Influenced by Response Measures and Disease Activity State. Annals of the Rheumatic Diseases, 2013, 72, A73.1-A73.	0.9	0
185	FRI0096â€Haq baseline values in an international registry of ra patients during the era of biologic terapies: the 2013 meteor database Annals of the Rheumatic Diseases, 2013, 72, A402.1-A402.	0.9	0
186	THU0593-HPRâ€Severe Fatigue is Highly Prevalent in ALL Rheumatic Diseases: an International Study. Annals of the Rheumatic Diseases, 2014, 73, 1197.3-1198.	0.9	0
187	Kyphoscoliosis: looking beyond the spine. BMJ Case Reports, 2015, 2015, bcr2014209096-bcr2014209096.	0.5	0
188	Systemic oxalosis in hyperoxaluria type 1. Rheumatology, 2017, 56, kew380.	1.9	0
189	AB1069â€The Educational Needs of People with Spondyloarthropathies (AS and PSA): A Cross-Sectional Study: Table 1 Annals of the Rheumatic Diseases, 2016, 75, 1267.2-1267.	0.9	0
190	Just a painful swelling of the ankles?. BMJ: British Medical Journal, 2018, 360, k436.	2.3	0
191	The leopard woman: a subacute and rare presentation. Rheumatology, 2018, 57, 428-428.	1.9	0
192	OP0160-HPRâ€Determinants of happiness and quality of life in patients with rheumatoid arthritis: a structural equation modelling approach. , 2018, , .		0
193	205 From zero to ten: difficulties in completing patient global assessment in rheumatoid arthritis: a mixed-methods study. Rheumatology, 2019, 58, .	1.9	0
194	FRI0123â€BIOLOGICAL THERAPIES SURVIVAL IN RHEUMATOID ARTHRITIS PATIENTSIN CLINICAL PRACTICE: RESULTS FROM THE METEOR REGISTRY. , 2019, , .		0
195	Comment on: â€ĩt can't be zero!' difficulties in completing patient global assessment in rheumatoid arthritis: a mixed methods study: reply. Rheumatology, 2021, 60, e30-e31.	1.9	0
196	Frequência de sÃndrome metabólica em estudantes de uma universidade pública brasileira. Research, Society and Development, 2021, 10, e37101219802.	0.1	0
197	Influência do perfil lipÃdico em placas ateroscleróticas coronarianas moderadas: análise com ultrassom intracoronariano. Revista Brasileira De Cardiologia Invasiva, 2009, 17, 88-93.	0.1	0
198	AB0179â€BEYOND DISEASE ACTIVITY, PAIN, "TIME―AND "TIMING―ACCOUNT FOR DISABILITY IN PA RHEUMATOID ARTHRITIS: RESULTS FROM A REAL-LIFE COHORT. Annals of the Rheumatic Diseases, 2020, 79,	TIENTS WI 0.9	TH O

1389-1389.

#	Article	IF	CITATIONS
199	SAT0184â€MAINTENANCE THERAPY WITH AZATHIOPRINE ASSOCIATED WITH HIGHER RISK OF FLARE IN PROLIFERATIVE LUPUS NEPHRITIS. Annals of the Rheumatic Diseases, 2020, 79, 1033-1034.	0.9	Ο
200	Reexamining remission definitions in rheumatoid arthritis: considering the 28â€joint Disease Activity Score, Câ€reactive protein level, and patient global assessment: comment on the article by Felson et al. Arthritis Care and Research, 2022, 74, 501-502.	3.4	0
201	Validation of Rheumatoid Arthritis Quality of Life (RAQoL) Questionnaire into Portuguese Language. Acta Reumatológica Portuguesa, 2019, 44, 65-70.	0.2	0
202	Diagnostic and therapeutic care pathway for fibromyalgia. Clinical and Experimental Rheumatology, 2021, 39 Suppl 130, 120-127.	0.8	0